Adjuvant immunotherapy in resected esophageal squamous cell carcinoma:a gospel to the non-pCRs  

作　　者：Zhihui Zhang Nan Sun Jie He 

机构地区：[1]Department of Thoracic Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [2]State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

出　　处：《Signal Transduction and Targeted Therapy》2021年第9期2611-2612,共2页信号转导与靶向治疗（英文）

基　　金：This work was supported by the CAMS Innovation Fund for Medical Sciences(2017-I2M-1-005).

摘　　要：A recent study1 published in The New England Journal of Medicine by Kelly RJ presented interim results from a phase 3 clinical trial(CheckMate 577),a global,randomized,double-blind,interventional trial to evaluate a novel approach of adjuvant nivolumab after neoadjuvant chemoradiotherapy(nCRT)and surgery for esophageal or gastroesophageal junction(GEJ)cancer.

关 键 词：ESOPHAGEAL clinical KELLY 

分 类 号：R735.1[医药卫生—肿瘤]